Zosano Pharma Corp (NASDAQ:ZSAN) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $10.00 for the company, according to Zacks. Zacks has also given Zosano Pharma an industry rank of 85 out of 256 based on the ratings given to related companies.
A number of equities analysts have recently commented on ZSAN shares. ValuEngine raised shares of Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research reissued a “buy” rating and issued a $3.00 price target on shares of Zosano Pharma in a research report on Saturday, August 24th.
NASDAQ:ZSAN opened at $2.00 on Tuesday. Zosano Pharma has a 12 month low of $1.85 and a 12 month high of $6.65. The firm has a market cap of $35.98 million, a price-to-earnings ratio of -0.53 and a beta of 2.66. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The company’s 50 day moving average is $2.50 and its 200-day moving average is $3.41.
Zosano Pharma (NASDAQ:ZSAN) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.01. Research analysts predict that Zosano Pharma will post -2.48 EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in ZSAN. Aisling Capital Management LP grew its stake in shares of Zosano Pharma by 900.0% in the second quarter. Aisling Capital Management LP now owns 16,000,000 shares of the biotechnology company’s stock worth $5,232,000 after acquiring an additional 14,400,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zosano Pharma by 118.6% in the second quarter. Vanguard Group Inc. now owns 957,025 shares of the biotechnology company’s stock worth $3,129,000 after acquiring an additional 519,305 shares during the last quarter. MYDA Advisors LLC acquired a new stake in shares of Zosano Pharma in the first quarter worth $343,000. BlackRock Inc. grew its stake in shares of Zosano Pharma by 17.7% in the second quarter. BlackRock Inc. now owns 366,876 shares of the biotechnology company’s stock worth $1,200,000 after acquiring an additional 55,105 shares during the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in shares of Zosano Pharma in the second quarter worth $68,000. Institutional investors and hedge funds own 33.37% of the company’s stock.
About Zosano Pharma
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Further Reading: What is an inverted yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.